Mr. Ron Nagar reports

TEMPRAMED EXPANDS LATIN AMERICAN DISTRIBUTION AGREEMENT WITH TEM AND RECEIVES ADDITIONAL COMMERCIAL ORDER, ANNOUNCES PRIVATE PLACEMENT

Tempramed Technologies Ltd. has entered into an amendment dated Sept. 23, 2026, to its definitive exclusive distribution agreement with TEM Consulting International SA, expanding the relationship beyond Panama into additional Latin American markets and adding Vivi Med to the distribution framework.

Highlights:

• Tempramed and TEM Consulting International execute amendment expanding the distribution relationship beyond Panama to additional Latin American markets;
• The amended framework adds Vivi Med to the covered product portfolio, alongside Vivi Cap and Vivi Epi;
• Tempramed received an additional commercial order from TEM, expected to be fulfilled by the end of September, 2026;
• Initial extended-territory framework contemplates minimum units across the added countries, with additional annual commitments tied to exclusivity;
• Once required registrations are completed, Tempramed products are expected to be available through distribution relationships covering seven Latin American countries representing a substantial majority of the region's population;
• Tempramed expects to raise up to $1-million through non-brokered private placement of units.

In connection with the amendment, Tempramed has received an additional commercial order from TEM, which the company expects to fulfill by the end of September, 2026. The additional order follows the previously announced transition of the parties' relationship from a non-binding LOI (letter of intent) into a definitive exclusive distribution agreement for Panama and reflects TEM's continued market-development activity for Tempramed products across the region.

The amendment extends the distribution territory to include Argentina, Venezuela, Colombia and Costa Rica, in addition to TEM's existing Panama relationship. Separately, Tempramed has previously announced distribution initiatives in Brazil and Mexico. Once required registrations and launch activities are completed in the applicable markets, Tempramed products are expected to be available through distribution relationships covering seven Latin American countries: Panama, Argentina, Venezuela, Colombia, Costa Rica, Mexico and Brazil.

Expanded commercial framework

The amended agreement includes an initial commercial extended-territory order across the added countries. Units under the initial extended-territory order may consist of any combination of Vivi Cap, Vivi Epi and Vivi Med, at TEM's election.

The amendment also adds Vivi Med to the products covered under the agreement. Vivi Med is designed to expand Tempramed's temperature-protection platform beyond standard insulin pens to include vials, biologics and other temperature-sensitive medications and supplies, supporting the company's broader portfolio strategy in Latin America.

TEM will be responsible, at its sole cost, for obtaining required governmental licences, registrations, approvals, importation authorizations, customs clearance, labelling compliance, and other regulatory or commercial requirements necessary to commercialize the products in each applicable country.

Seven-country Latin American coverage opportunity

With the existing Panama agreement, the expanded territory under the amended agreement, and Tempramed's separate Brazil and Mexico initiatives, the company is building a distribution footprint that is expected to cover seven countries in South and Central America once products are registered in each applicable market.

Management believes this represents an important regional-scale opportunity. Based on World Bank population data, Latin America and the Caribbean had approximately 666.6 million people in 2025. The seven countries covered by Tempramed's current and contemplated distribution initiatives collectively represent more than 70 per cent of that regional population.

Latin America is an important growth region for Tempramed because many patients use temperature-sensitive medications in hot climates and in settings where daily travel, pharmacy-to-home transport, outdoor work, power interruptions and fragmented health care access can increase the risk of medication temperature exposure. Tempramed's product portfolio is designed to provide practical, passive, reusable protection for insulin, GLP-1 therapies, biologics, epinephrine auto-injectors, vials and other temperature-sensitive medications without batteries, charging or external power.

The expanded relationship with TEM supports Tempramed's strategy to build a scalable international distribution network through established health care distributors, clinics, pharmacies and medical channels. Management believes the addition of Vivi Med further broadens the commercial opportunity by extending the company's product offering to additional medication formats and higher-value therapeutic categories.

"The expansion of our relationship with TEM marks another important step in converting our international distribution strategy into commercial execution," said Ron Nagar, chief executive officer of Tempramed. "We began with Panama, moved into a definitive agreement, fulfilled an initial commercial order and are now expanding the relationship into additional Latin American markets while receiving another commercial order expected to be fulfilled by the end of September. This is exactly the type of execution progress we want to demonstrate to investors."

"Once required registrations are completed, this relationship and our broader Latin American initiatives are expected to provide access to seven countries representing a substantial majority of the region's population," added Mr. Nagar. "The addition of Vivi Med is also significant because it expands our addressable opportunity beyond insulin pens to vials, biologics and other temperature-sensitive medications. We believe this creates a stronger, more diversified platform for long-term growth in Latin America."

Private placement

Tempramed also announces a non-brokered private placement of up to two million units of the company at a price of 50 cents per unit for aggregate gross proceeds of up to $1-million. Each unit will consist of one common share of the company and one share purchase warrant of the company. Each warrant will entitle the holder thereof to purchase one additional share at a price of $1 at any time on or before the date which is 18 months after the closing date of the offering.

The proposed use of proceeds from the offering is to finance new inventory and product development, to scale the sales and marketing division globally, as well as for general working capital.

In accordance with applicable securities laws, the shares, warrants and any additional shares issued upon exercise of the warrants will be subject to a four-month-and-one-day hold period in Canada from the date of closing of the offering. The warrants issued to certain of the investors will be subject to a restriction preventing their exercise if such exercise would result in the holder holding over 9.99 per cent of the issued and outstanding shares of the company. Accordingly, it is anticipated that there will be no new insiders as a result of the offering.

Closing of the offering is anticipated to occur on or before Sept. 30, 2026, or such other date or dates as may be determined by the company, subject to the receipt of investor documentation, funds and compliance with the requirements of the Canadian Securities Exchange.

In connection with the offering, the company may pay finders' fees to certain qualified arm's-length parties consisting of cash finders' fees equal to 7 per cent of the gross proceeds raised and a number of common shares equal to 7 per cent of the number of units placed by such finder.

About Tempramed Technologies Ltd.

Tempramed Technologies is a global medical-device company with a portfolio of innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, Tempramed develops patented, FDA-registered (U.S. Food and Drug Administration) thermal insulation devices that work 24 hours a day, seven days a week without batteries or external power. With a product line already in market including Vivi Cap, Vivi Cap Smart, Vivi Epi and Vivi Med, Tempramed enables patients and health care providers to confidently manage temperature-sensitive medications anywhere, any time. With operations in North America, Europe and Asia, Tempramed continues to expand globally with solutions for medication protection and adherence.

We seek Safe Harbor.